Thank you for your interest in Synaptiq Psychiatry. We are currently accepting consultation requests to join our priority waitlist.

Frequently Asked Questions

Below are common questions about our clinic. Feel free to contact us if you don’t see your question answered here.

What is a psychiatrist?
What region do you serve?
How does the mobile clinic work?
Do you see children/adolescents?
Do you offer free consultations?
What is your response time for messages?
How do your membership plans work?
Do you prescribe controlled substances?
What is psychiatric psychotherapy?
What is nature psychotherapy?
What is TMS?
What is ketamine therapy?
Who may benefit from TMS or ketamine therapy?
Are TMS/ketamine treatments safe? Are there any side effects?
How long does TMS/ketamine treatment take to work?
How successful is TMS/ketamine therapy?
What does a TMS/ketamine session entail?
What is maintenance TMS?
TMS vs. ketamine therapy: which should I choose?
What should I expect at my first appointment?
Will treatment options be discussed right away?
Do I have to transfer my care to you after the consultation?
What is a second opinion consultation, and who should consider one?
What is a second opinion consultation?
What are follow-up appointments like?
How long are follow-up visits?
How often will I need to be seen?
What kind of support is available between visits?
How do medication refills work between visits?
What if I can't make a scheduled appointment?
Can I submit a bill to my insurance company on my own?
Are you in network with insurance?
What does out of network mean for me?
Will I get reimbursed?
How do I submit for reimbursement?
Why don't you take insurance?

References

  1. Joschko, L., Pálsdóttir, A. M., Grahn, P., & Hinse, M. (2023). Nature-Based Therapy in Individuals with Mental Health Disorders, with a Focus on Mental Well-Being and Connectedness to Nature-A Pilot Study. International journal of environmental research and public health, 20(3), 2167. https://doi.org/10.3390/ijerph20032167 
  2. Rossi, S., Antal, A., Bestmann, S., Bikson, M., Brewer, C., Brockmöller, J., Carpenter, L. L., Cincotta, M., Chen, R., Daskalakis, J. D., Di Lazzaro, V., Fox, M. D., George, M. S., Gilbert, D., Kimiskidis, V. K., Koch, G., Ilmoniemi, R. J., Lefaucheur, J. P., Leocani, L., Lisanby, S. H., … basis of this article began with a Consensus Statement from the IFCN Workshop on “Present, Future of TMS: Safety, Ethical Guidelines”, Siena, October 17-20, 2018, updating through April 2020 (2021). Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology, 132(1), 269–306. https://doi.org/10.1016/j.clinph.2020.10.003 
  3. Bahji, A., Zarate, C. A., & Vazquez, G. H. (2022). Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. Expert opinion on drug safety, 21(6), 853–866. https://doi.org/10.1080/14740338.2022.2047928 
  4. Vida, R., Sághy, E., Bella, R. et al. (2023). Efficacy of repetitive transcranial magnetic stimulation (rTMS) adjunctive therapy for major depressive disorder (MDD) after two antidepressant treatment failures: meta-analysis of randomized sham-controlled trials. BMC Psychiatry, 23, Article 545. https://doi.org/10.1186/s12888-023-05033-y 
  5. Philip, N. S., Barredo, J., Aiken, E., Larson, V., Jones, R. N., Shea, M. T., Greenberg, B. D., & van ‘t Wout-Frank, M. (2019). Theta-Burst Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder. The American Journal of Psychiatry, 176(11), 939–948. https://doi.org/10.1176/appi.ajp.2019.18101160
  6. Caulfield, K. A., Fleischmann, H. H., George, M. S., & McTeague, L. M. (2022). A transdiagnostic review of safety, efficacy, and parameter space in accelerated transcranial magnetic stimulation. Journal of Psychiatric Research, 152, 384–396. https://doi.org/10.1016/j.jpsychires.2022.06.038 
  7. Hearne, L. J., Webb, L., Cash, R., Robinson, C., Mosley, P. E., Ng, J., Thwaites, S. T., Issa, S., Miller, J., Tse, N. Y., Zalesky, A., Burgher, B., & Cocchi, L. (2025). Clinical and neurophysiological effects of robotically-delivered fMRI-guided personalized transcranial magnetic stimulation therapy for depression. Psychotherapy and Psychosomatics, 94(4), 225–231. https://doi.org/10.1159/000545692
  8. Bahji, A., Vazquez, G. H., & Zarate, C. A., Jr (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 278, 542–555. https://doi.org/10.1016/j.jad.2020.09.071 

Ready to get started?

Click below to begin a secure screening. If you’re a good fit, we’ll guide you through scheduling and next steps.